使用医用大麻的原因和预期效果:一项全州范围的横断面调查。

Q1 Medicine
Medical Cannabis and Cannabinoids Pub Date : 2024-07-30 eCollection Date: 2024-01-01 DOI:10.1159/000540593
Ruba Sajdeya, Sebastian Jugl, Yan Wang, Juan G Perez, Sophie Maloney, Catalina Lopez-Quintero, Amie J Goodin, Almut G Winterstein, Robert L Cook
{"title":"使用医用大麻的原因和预期效果:一项全州范围的横断面调查。","authors":"Ruba Sajdeya, Sebastian Jugl, Yan Wang, Juan G Perez, Sophie Maloney, Catalina Lopez-Quintero, Amie J Goodin, Almut G Winterstein, Robert L Cook","doi":"10.1159/000540593","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Medical cannabis (MC) is available upon certification for one of several qualifying conditions in Florida, USA. Previous studies suggested that some people seek cannabis for medical conditions/symptoms beyond those legally permitted. However, data remain limited on patient motives for seeking MC and their experiences around its impact on their health. We aimed to compare reported qualifying conditions for MC certification with the most frequently self-reported reasons for using MC while assessing the alignment between the two and understanding the perceived impacts of MC on self-reported conditions and symptoms.</p><p><strong>Methods: </strong>We conducted a cross-sectional study using survey data from the Medical Marijuana and Me (M<sup>3</sup>) Data Bank of individuals receiving MC in Florida, USA, in 2022. Participants were recruited via convenience sampling from nine MC clinics/clinic networks across Florida and were asked to fill out an online survey. The study measures included sociodemographic variables, self-reported health conditions, self-reported main reasons for using MC, self-reported qualifying conditions for MC certification, and self-reported perceived impact of MC on health conditions. We cross-tabulated reported qualifying conditions and reasons for MC use and reported the perceived impact per condition.</p><p><strong>Results: </strong>A total of 632 participants completed the survey, of whom 396 (62.66%) were female and 471 (74.53%) were non-Hispanic white. The median (IQR) age was 45 (35, 58). The most frequently reported qualifying conditions were post-traumatic stress disorder (PTSD) (<i>n</i> = 187, 29.59%), a condition not on the qualifying conditions list (<i>n</i> = 175, 27.69%), medical conditions of the same kind/comparable to those listed (<i>n</i> = 140, 22.15%), and chronic nonmalignant pain (<i>n</i> = 62, 25.63%). The top ten most frequently reported reasons for using MC were anxiety (<i>n</i> = 383, 60.60%), chronic pain (<i>n</i> = 278, 43.99%), depression (<i>n</i> = 252, 39.87%), PTSD (<i>n</i> = 220, 34.81%), headaches/migraine (<i>n</i> = 134, 21.20%), fibromyalgia (<i>n</i> = 67, 10.60%), attention-deficit hyperactivity disorder (ADHD) (<i>n</i> = 59, 9.34%), bipolar disorder (<i>n</i> = 53, 8.39%), high blood pressure (<i>n</i> = 41, 6.49%), and cancer (<i>n</i> = 18,2.85%). Of respondents, 70-90% with each qualifying condition reported it as one of the main reasons for using MC. Most respondents reported improvement of anxiety (<i>n</i> = 430/451, 95.34%), depression (<i>n</i> = 381/392, 97.20%), chronic pain (<i>n</i> = 305/310, 98.39%), insomnia/sleeping problems (<i>n</i> = 225/295, 86.44%), PTSD (<i>n</i> = 247/270, 91.48%), headaches/migraine (<i>n</i> = 172/218, 78.90%), ADHD (<i>n</i> = 82/123, 66.67%), bipolar disorder (<i>n</i> = 79/89, 88.76%), and fibromyalgia (<i>n</i> = 77/82, 93.90%). Most respondents were unsure/reported no change in blood pressure (<i>n</i> = 93/162, 57.41%). A small percentage reported perceived worsening impacts on their conditions.</p><p><strong>Conclusion: </strong>Qualifying conditions and self-reported reasons for using MC aligned for most respondents. Yet, a notable proportion of respondents sought MC for broader treatment effects beyond those delineated by the officially recognized qualifying conditions in Florida, USA. Most patients perceived positive effects, including those with limited available evidence on efficacy.</p>","PeriodicalId":18415,"journal":{"name":"Medical Cannabis and Cannabinoids","volume":"7 1","pages":"138-148"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521456/pdf/","citationCount":"0","resultStr":"{\"title\":\"Reasons for Use and Perceived Effects of Medical Cannabis: A Cross-Sectional Statewide Survey.\",\"authors\":\"Ruba Sajdeya, Sebastian Jugl, Yan Wang, Juan G Perez, Sophie Maloney, Catalina Lopez-Quintero, Amie J Goodin, Almut G Winterstein, Robert L Cook\",\"doi\":\"10.1159/000540593\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Medical cannabis (MC) is available upon certification for one of several qualifying conditions in Florida, USA. Previous studies suggested that some people seek cannabis for medical conditions/symptoms beyond those legally permitted. However, data remain limited on patient motives for seeking MC and their experiences around its impact on their health. We aimed to compare reported qualifying conditions for MC certification with the most frequently self-reported reasons for using MC while assessing the alignment between the two and understanding the perceived impacts of MC on self-reported conditions and symptoms.</p><p><strong>Methods: </strong>We conducted a cross-sectional study using survey data from the Medical Marijuana and Me (M<sup>3</sup>) Data Bank of individuals receiving MC in Florida, USA, in 2022. Participants were recruited via convenience sampling from nine MC clinics/clinic networks across Florida and were asked to fill out an online survey. The study measures included sociodemographic variables, self-reported health conditions, self-reported main reasons for using MC, self-reported qualifying conditions for MC certification, and self-reported perceived impact of MC on health conditions. We cross-tabulated reported qualifying conditions and reasons for MC use and reported the perceived impact per condition.</p><p><strong>Results: </strong>A total of 632 participants completed the survey, of whom 396 (62.66%) were female and 471 (74.53%) were non-Hispanic white. The median (IQR) age was 45 (35, 58). The most frequently reported qualifying conditions were post-traumatic stress disorder (PTSD) (<i>n</i> = 187, 29.59%), a condition not on the qualifying conditions list (<i>n</i> = 175, 27.69%), medical conditions of the same kind/comparable to those listed (<i>n</i> = 140, 22.15%), and chronic nonmalignant pain (<i>n</i> = 62, 25.63%). The top ten most frequently reported reasons for using MC were anxiety (<i>n</i> = 383, 60.60%), chronic pain (<i>n</i> = 278, 43.99%), depression (<i>n</i> = 252, 39.87%), PTSD (<i>n</i> = 220, 34.81%), headaches/migraine (<i>n</i> = 134, 21.20%), fibromyalgia (<i>n</i> = 67, 10.60%), attention-deficit hyperactivity disorder (ADHD) (<i>n</i> = 59, 9.34%), bipolar disorder (<i>n</i> = 53, 8.39%), high blood pressure (<i>n</i> = 41, 6.49%), and cancer (<i>n</i> = 18,2.85%). Of respondents, 70-90% with each qualifying condition reported it as one of the main reasons for using MC. Most respondents reported improvement of anxiety (<i>n</i> = 430/451, 95.34%), depression (<i>n</i> = 381/392, 97.20%), chronic pain (<i>n</i> = 305/310, 98.39%), insomnia/sleeping problems (<i>n</i> = 225/295, 86.44%), PTSD (<i>n</i> = 247/270, 91.48%), headaches/migraine (<i>n</i> = 172/218, 78.90%), ADHD (<i>n</i> = 82/123, 66.67%), bipolar disorder (<i>n</i> = 79/89, 88.76%), and fibromyalgia (<i>n</i> = 77/82, 93.90%). Most respondents were unsure/reported no change in blood pressure (<i>n</i> = 93/162, 57.41%). A small percentage reported perceived worsening impacts on their conditions.</p><p><strong>Conclusion: </strong>Qualifying conditions and self-reported reasons for using MC aligned for most respondents. Yet, a notable proportion of respondents sought MC for broader treatment effects beyond those delineated by the officially recognized qualifying conditions in Florida, USA. Most patients perceived positive effects, including those with limited available evidence on efficacy.</p>\",\"PeriodicalId\":18415,\"journal\":{\"name\":\"Medical Cannabis and Cannabinoids\",\"volume\":\"7 1\",\"pages\":\"138-148\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521456/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Cannabis and Cannabinoids\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000540593\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Cannabis and Cannabinoids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000540593","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

简介:在美国佛罗里达州,医用大麻(Medical cannabis,MC)经认证可用于治疗几种符合条件的病症之一。之前的研究表明,一些人寻求大麻治疗的病症/症状超出了法律允许的范围。然而,有关患者寻求使用大麻的动机以及大麻对其健康的影响的数据仍然有限。我们的目的是将所报告的获得 MC 认证的合格条件与最常自我报告的使用 MC 的原因进行比较,同时评估两者之间的一致性,并了解 MC 对自我报告的病情和症状的影响:我们利用 "医用大麻与我"(M3)数据库中的调查数据,对 2022 年在美国佛罗里达州接受医用大麻治疗的个人进行了一项横断面研究。我们从佛罗里达州的九家医用大麻诊所/诊所网络中通过便利抽样的方式招募参与者,并要求他们填写一份在线调查问卷。研究措施包括社会人口变量、自我报告的健康状况、自我报告的使用 MC 的主要原因、自我报告的 MC 认证合格条件以及自我报告的 MC 对健康状况的影响。我们对所报告的合格条件和使用 MC 的原因进行了交叉分析,并报告了每种条件的可感知影响:共有 632 名参与者完成了调查,其中 396 人(62.66%)为女性,471 人(74.53%)为非西班牙裔白人。年龄中位数(IQR)为 45(35,58)。最常报告的合格病症是创伤后应激障碍(PTSD)(187 人,占 29.59%)、不在合格病症列表中的病症(175 人,占 27.69%)、与列表中病症相同/相似的病症(140 人,占 22.15%)和慢性非恶性疼痛(62 人,占 25.63%)。最常报告的使用 MC 的十大原因是焦虑(n = 383,60.60%)、慢性疼痛(n = 278,43.99%)、抑郁(n = 252,39.87%)、创伤后应激障碍(n = 220,34.81%)、头痛/偏头痛(n = 134,21.20%)、纤维肌痛(n = 67,10.60%)、注意力缺陷多动障碍(ADHD)(n = 59,9.34%)、双相情感障碍(n = 53,8.39%)、高血压(n = 41,6.49%)和癌症(n = 18,2.85%)。在受访者中,70%-90%的受访者表示,每种符合条件的疾病都是使用 MC 的主要原因之一。大多数受访者表示焦虑(430/451,95.34%)、抑郁(381/392,97.20%)、慢性疼痛(305/310,98.39%)、失眠/睡眠问题(225/295,86.44%)、创伤后应激障碍(n = 247/270,91.48%)、头痛/偏头痛(n = 172/218,78.90%)、多动症(n = 82/123,66.67%)、躁郁症(n = 79/89,88.76%)和纤维肌痛(n = 77/82,93.90%)。大多数受访者不确定/报告血压没有变化(n = 93/162,57.41%)。小部分受访者表示他们认为自己的病情恶化了:结论:大多数受访者的病情和自述的使用 MC 的原因是一致的。然而,在美国佛罗里达州,有相当一部分受访者寻求 MC 的目的是为了获得更广泛的治疗效果,而不是官方认可的合格病症。大多数患者都能感受到积极的疗效,包括那些疗效证据有限的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Reasons for Use and Perceived Effects of Medical Cannabis: A Cross-Sectional Statewide Survey.

Introduction: Medical cannabis (MC) is available upon certification for one of several qualifying conditions in Florida, USA. Previous studies suggested that some people seek cannabis for medical conditions/symptoms beyond those legally permitted. However, data remain limited on patient motives for seeking MC and their experiences around its impact on their health. We aimed to compare reported qualifying conditions for MC certification with the most frequently self-reported reasons for using MC while assessing the alignment between the two and understanding the perceived impacts of MC on self-reported conditions and symptoms.

Methods: We conducted a cross-sectional study using survey data from the Medical Marijuana and Me (M3) Data Bank of individuals receiving MC in Florida, USA, in 2022. Participants were recruited via convenience sampling from nine MC clinics/clinic networks across Florida and were asked to fill out an online survey. The study measures included sociodemographic variables, self-reported health conditions, self-reported main reasons for using MC, self-reported qualifying conditions for MC certification, and self-reported perceived impact of MC on health conditions. We cross-tabulated reported qualifying conditions and reasons for MC use and reported the perceived impact per condition.

Results: A total of 632 participants completed the survey, of whom 396 (62.66%) were female and 471 (74.53%) were non-Hispanic white. The median (IQR) age was 45 (35, 58). The most frequently reported qualifying conditions were post-traumatic stress disorder (PTSD) (n = 187, 29.59%), a condition not on the qualifying conditions list (n = 175, 27.69%), medical conditions of the same kind/comparable to those listed (n = 140, 22.15%), and chronic nonmalignant pain (n = 62, 25.63%). The top ten most frequently reported reasons for using MC were anxiety (n = 383, 60.60%), chronic pain (n = 278, 43.99%), depression (n = 252, 39.87%), PTSD (n = 220, 34.81%), headaches/migraine (n = 134, 21.20%), fibromyalgia (n = 67, 10.60%), attention-deficit hyperactivity disorder (ADHD) (n = 59, 9.34%), bipolar disorder (n = 53, 8.39%), high blood pressure (n = 41, 6.49%), and cancer (n = 18,2.85%). Of respondents, 70-90% with each qualifying condition reported it as one of the main reasons for using MC. Most respondents reported improvement of anxiety (n = 430/451, 95.34%), depression (n = 381/392, 97.20%), chronic pain (n = 305/310, 98.39%), insomnia/sleeping problems (n = 225/295, 86.44%), PTSD (n = 247/270, 91.48%), headaches/migraine (n = 172/218, 78.90%), ADHD (n = 82/123, 66.67%), bipolar disorder (n = 79/89, 88.76%), and fibromyalgia (n = 77/82, 93.90%). Most respondents were unsure/reported no change in blood pressure (n = 93/162, 57.41%). A small percentage reported perceived worsening impacts on their conditions.

Conclusion: Qualifying conditions and self-reported reasons for using MC aligned for most respondents. Yet, a notable proportion of respondents sought MC for broader treatment effects beyond those delineated by the officially recognized qualifying conditions in Florida, USA. Most patients perceived positive effects, including those with limited available evidence on efficacy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Cannabis and Cannabinoids
Medical Cannabis and Cannabinoids Medicine-Complementary and Alternative Medicine
CiteScore
6.00
自引率
0.00%
发文量
18
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信